Teza Capital Management LLC Purchases New Holdings in Kura Oncology, Inc. $KURA

Teza Capital Management LLC purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 24,602 shares of the company’s stock, valued at approximately $162,000.

Other institutional investors have also recently added to or reduced their stakes in the company. State of Wyoming acquired a new position in Kura Oncology in the 1st quarter valued at about $48,000. Pallas Capital Advisors LLC acquired a new position in Kura Oncology in the 1st quarter valued at about $66,000. Flower City Capital acquired a new position in Kura Oncology in the 1st quarter valued at about $79,000. Magnetar Financial LLC acquired a new position in Kura Oncology in the 1st quarter valued at about $79,000. Finally, E Fund Management Co. Ltd. increased its position in Kura Oncology by 18.9% in the 1st quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company’s stock valued at $81,000 after acquiring an additional 1,951 shares during the period.

Analysts Set New Price Targets

Several equities analysts recently issued reports on KURA shares. JMP Securities dropped their price target on Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating on the stock in a research report on Monday, August 11th. Mizuho cut their price target on shares of Kura Oncology from $32.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, May 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 26th. Wall Street Zen raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. Finally, Guggenheim initiated coverage on shares of Kura Oncology in a report on Thursday, September 4th. They set a “neutral” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $24.10.

Insider Transactions at Kura Oncology

In related news, CEO Troy Edward Wilson bought 50,000 shares of the company’s stock in a transaction on Monday, September 8th. The stock was bought at an average cost of $8.20 per share, with a total value of $410,000.00. Following the completion of the acquisition, the chief executive officer owned 100,968 shares in the company, valued at approximately $827,937.60. This represents a 98.10% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.40% of the company’s stock.

Kura Oncology Trading Down 1.6%

Shares of Kura Oncology stock opened at $8.01 on Wednesday. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $21.40. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. The stock has a market cap of $695.27 million, a PE ratio of -3.54 and a beta of 0.19. The company has a 50-day moving average of $6.76 and a two-hundred day moving average of $6.57.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The business had revenue of $15.29 million for the quarter, compared to the consensus estimate of $64.95 million. On average, research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.